When you’re focusing on the future of cancer care, it helps to start with a clear and accurate picture of the present.
COTA leverages our proprietary abstraction technology and oncology expertise to curate meaningful, longitudinal, and de-identified data to enable insight generation. We form flexible and collaborative partnerships with life science companies to shape the future of real world evidence.
Market of current oncologics and decisions to drive future therapeutic areas.
Read Customer Case Study:
Drug development and build real world comparator arms.
Read Customer Case Study:
New ways of thinking about how trials are designed.
Read Customer Case Study:
Records sourced from tertiary referral centers capture complex and advanced cancers with rigorous EMR documentation and genomic profiling capabilities.
Technology enabled human abstraction allows for nuances in unstructured data to be captured by medical professionals.
Solution oriented agility enables rapid assessment and implementation of augmentation requests.
COTAs standard level dataset goes deeper than traditional sources, capturing the clinical information that is most valuable to life sciences.
Clinicogenomics data
can be added to Focus
Find answers to the most common questions about Cotas services for life sciences.
COTA captures clinical data from EHR from multiple provider sources across the United States, including both academic and community cancer programs. We also use non-EHR sources such as publicly available and proprietary databases, to generate a rich and precise dataset for use by life sciences companies.
COTA collects all clinically-relevant data points to create a rich, in-depth longitudinal cancer patient journey from our healthcare providers’ EHR. Data elements captured may vary per cancer type, but generally, our data contains (but is not limited to) detailed demographic, pathologic, genomic, treatment, and outcomes data.
We work with life science companies interested in using oncology RWD to accelerate drug development and bring clarity to cancer. We work with the top global pharmaceutical companies, though our partners range from multinational pharma to emerging biotechs.
The FDA plays an incredibly important role in the process of developing, distributing, and monitoring therapeutic products. So when something changes at the FDA, the entire life sciences community sits up and takes notice. In recent months, those changes have come fast and furious as the new administration seeks to put its priorities into action. […]
…
Real-world data (RWD) from electronic health records (EHRs) is increasingly recognized as a powerful asset for oncology research. It enables stakeholders across industry and academia to evaluate treatment patterns, assess comparative effectiveness, identify safety signals, and inform regulatory and market access strategies. RWD has supported external control arms, augmented clinical trial enrollment, and generated post-marketing […]
…
At COTA, we believe the future of healthcare is shaped not only by innovation and data but by people. Each summer, we’re excited to welcome a group of bright, driven interns who bring fresh perspectives, unique talents, and a shared passion for meaningful impact. This year is no exception. Our 2025 intern class includes students […]
…Interested in learning more about how we can transform cancer care together?
